Evoke Pharma Revenue, Profits - EVOK Annual Income Statement

Add to My Stocks
$2.65 $0.06 (2.21%) EVOK stock closing price Jun 21, 2018 (Closing)

EVOK stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Evoke Pharma stock price. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. Like any other income statement, the EVOK income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of 0 when compared to the same period in the past. The operating expenses as shown in the Evoke Pharma profit and loss statement for 2017 total to $11.22M. This line item shows that the operating expenses has increased compared with last year. Also check: Evoke Pharma assets and Evoke Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Evoke Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-------
Evoke Pharma Gross Profit
Research & Development Expense7.13M6.95M8.15M9.99M-1.16M1.84M
Selling General & Admin Expense4.09M3.59M3.66M3.15M1.64M--
Income Before Depreciation Depletion Amortization-11.23M-10.54M-11.81M-13.15M-2.6M-2M-2.41M
Depreciation Depletion Amortization-------
Non Operating Income-1M--0.3M--0.07M--
Interest Expense-0.01M------
Evoke Pharma Pretax Income
Provision for Income Taxes-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-12.22M-10.74M-12.12M-13.24M-2.83M-2.01M-2.4M
Extraordinary Items & Discontinued Operations-------
Evoke Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS14.95M9.34M6.49M6.03M2.37M3.56M-
Average Shares used to compute Basic EPS14.9M9.34M6.49M6.03M2.37M3.56M-
Income Before Nonrecurring Items-11.23M-11.35M-12.12M-13.25M-2.84M-2.02M-
Income from Nonrecurring Items-1.01M------
Evoke Pharma Earnings Per Share Basic Net
Evoke Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.83-1.21-1.87-2.20-1.20-0.57-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Evoke Pharma stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the Evoke Pharma revenue chart, as isn't the case with Evoke Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of EVOK stock with its peers like GNMX stock and VSAR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-12.22M for EVOK stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the EVOK income statement, one can check the Evoke Pharma historical stock prices to check how the price has moved with time.

Evoke Pharma Income Statement - Key Financial Ratios